Postpartum depression (PPD) is one of the most common medical complications that can come with pregnancy.4-10 During pregnancy, levels of certain hormones rise and then rapidly fall after giving birth. These hormone shifts may put some women at risk for developing this serious disorder.11
PPD can impact a new mom’s ability to function, her mood, and/or her interest in caring for her newborn. Signs and symptoms could include persistent sad, anxious, or “empty mood”; feelings of guilt, worthlessness, hopelessness, or helplessness; fatigue or abnormal decrease in energy; difficulty concentrating, remembering, or making decisions; and abnormal appetite, weight changes, or both.12
Sage's lead product, ZULRESSO® (brexanolone) CIV, was approved in 2019 by the Food and Drug Administration (FDA) and is indicated for the treatment of postpartum depression (PPD) in patients 15 years and older. ZURZUVAE®
(zuranolone) CIV, in collaboration with Biogen, was approved in August of 2023 by the FDA as an oral medication for the treatment of adults with PPD.13, 14